Navigation Links
Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
Date:4/25/2008

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

In a late-breaking abstract presented at the 1st European Lung Cancer Conference jointly organized by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), Prof. Giorgio Scagliotti from the University of Torino, Italy presented data from the clinical trial stopped in February.

For some patients, the drug results in worse outcomes. "Based on a planned interim analysis the study showed a clear inferiority from adding sorafenib to carboplatin/paclitaxel in first-line non-small-cell lung cancer patients with squamous histology," Prof. Scagliotti said.

Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.

The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.

After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.

"To date there is no evidence of any detrimental effect from sorafenib in additional subgroups of patients," Prof. Scagliotti said.

He noted that researchers are still studying the drug in lung cancer, including an ongoing study examining adding it to the combination of cisplatin and gemcitabine.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Invention gives improved gene technology analysis
2. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
3. Genome analysis reveals new protein associated with breast cancer progression
4. Analysis Highlights Economic Contribution of Hospitals to Communities
5. SAIC Awarded DIA Intelligence Analysis Contract
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. Some Cancer Trials Overstate Findings, Analysis Claims
10. Review of group-based cancer trials reveals flaws in studies design and analysis
11. Stanford University School of Medicine to Address Improving Network Security and Management at EDUCAUSE Western Regional Conference 2008 Using Lancopes StealthWatch System for Network Behavior Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... The Ellis Agency, ... with the Epilepsy Foundation in a community wide charity event with the goal of ... Sunde, a young local woman who lives with epilepsy, recently launched a charity campaign ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... Pace Analytical, a company of over 2,000 employees and a leader in environmental ... Sciences, further solidifying their position as the top American owned and operated environmental ... ... Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative full ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
Breaking Medicine Technology: